In spite of the fact that the American medicine "Sofosbuvir" in September was recognized as vital, it hasn't got to purchases because of too high price: packing costs more than 100 thousand rubles of the Photo: depositphotos.com the Ministry of Health was included by Sofosbuvir — the most effective hepatitis C medicine — in the order for the next year though on September 4 the interdepartmental commission recognized it as the vital medicine, RBC reports. Representatives of the Ministry of Health at a meeting of the commission spoke about efficiency of Sofosbuvir: affects all types of a virus, a minimum of side effects, the course of treatment is shorter, a form — tablets, but not injections, we will combine with other drugs. The head of department of control of the social sphere and trade of FAS Timofey Nizhegorodtsev hinted that not to meet the budget. Packing of medicine in purchase costs more than 100 thousand rubles, and on a course three packs are necessary. The director of the department of provision of medicines of the Ministry of Health Elena Maksimkina has agreed with him, and here patients — a net:maksimkina: The medicine "Sofosbuvir" with the price which is stated now by the producer doesn't keep within budget opportunities. Though, certainly, all medical community supports availability of such medicines. Therefore, Timofey Vitalyevich, probably, it is necessary to turn on mechanisms already. We just need to reduce the price significantly in the nearest future. Nizhegorodtsev: In some countries licenses for production, and there other price are obtained. Representative of patient community: At us very strange situation has turned out that this medicine is registered 2,5 years in Russia, and we can't receive it in any way. People to whom interferon therapy on vital indicators is impossible can't receive treatment. Maksimkina: According to vital indications have to provide, and it is responsibility of all bodies of health care on places. The government hasn't approved the list of the vital drugs the next year yet, but in the application there is no Sofosbuvir any more though all other medicines recommended by the interdepartmental commission are present. High price — the main reason why the Ministry of Health won't begin to buy this medicine. The deputy director general of Humanitarian Action charity foundation Alexey Lakhov:aleksey Lakhov of the deputy director general of Humanitarian Action charity foundation "Argues on consequences missing in these purchases, of course, strongly disturbs us because Sofosbuvir in application, let us assume, with Daklatasvir which too is already included into the VED list is the key scheme just because affects all genotypes of a virus. And now again doctors should combine schemes from different other medicines. Specifically this scheme could capture really very big pool of patients. Specifically at Sofosbuvir and Daklatasvir very high rate of treatment — more than 90%. Medicine has been registered in 2016, and still it didn't join in the VED list because of the price, at last, it was included this year, but now it turns out that isn't wanted to be bought all the same at this price. Also it turns out again,
From Astana to Nursultan — one step
Date: 2019-03-22 05:002 hrs ago
The authorities of Kazakhstan approved renaming of the capital. However it became clear that this decision not all citizens Astana support, Kazakhstan. Photo: the parliament of Kazakhstan approved by...
View details »
Volvo cars will operate drivers
Date: 2019-03-21 22:009 hrs ago
At the beginning of the 2020th years the company plans to introduce in the cars systems for control of drivers. Before Volvo decided to limit the speed of the cars to 180 kilometers per hour of the Ph...
View details »